Misuse of Antibiotic during COVID 19 Outbreaks
Abstract
The COVID-19 outbreak, caused by the severe acute respiratory syndrome coronavirus 2, has been detected in December 2019 in Wuhan, China, and is accompanied by significant degrees of morbidity and mortality. Antibiotic resistance (AMR) threatens to wreak havoc on healthcare system and the impact of globalization, and COVID-19 is intended to keep it at bay for the time being. During the COVID-19 crisis, a wide range of antimicrobial medicines were promoted as viable treatments. While both industrialized and industrializing nations have seen a rise in antimicrobial medication usage, use and abuse have been significantly more prevalent in developing countries. Antibiotic resistance is still a concern since microorganisms that cause resistant infections develop in hospitals and medical institutions, placing all patients at risk, complicating the care of COVID-19. Improper prescriptions, a lack of care management policies and needless self-administration by the general population are examples of these. Antibiotics seem to be more motivated to abuse and misusing antibiotics than to keep them safe and take them only when prescribed. Almost all of the substantial antibiotic usage in COVID-19 patients is inevitable. Patients having lung viral infections are more likely to develop subsequent bacterial infections, which lead to higher disease severity and death. Immediately crucial components of any AMR mitigation approach are increased spending in education and increased public knowledge of AMR. More studies are needed to better understand the health risks and rate of co-infection in COVID-19 patients in order to promote a decrease in any unnecessary antimicrobial prescribing.
Keywords: COVID-19; Antibiotic use and misuse; Antimicrobial Resistance.
Keywords:
COVID-19, Antibiotic use and misuse, Antimicrobial ResistanceDOI
https://doi.org/10.22270/jddt.v11i6-S.5102References
Rodriguez-Morales AJ, Bonilla-Aldana DK, Balbin-Ramon GJ, Rabaan AA, Sah R, Paniz-Mondolfi A, Pagliano P, Esposito S. History is repeating itself: Probable zoonotic spillover as the cause of the 2019 novel Coronavirus Epidemic. Infez Med. 2020; 28(1):3-5.
Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses. 2020; 12(2):135. https://doi.org/10.3390/v12020135.
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2):271-280.e8. https://doi.org/10.1016/j.cell.2020.02.052.
Fehr AR, Channappanavar R, Perlman S. Middle East Respiratory Syndrome: Emergence of a Pathogenic Human Coronavirus. Annu Rev Med. 201714; 68:387-399. https://doi.org/10.1146/annurev-med-051215-031152.
Shallcross LJ, Howard SJ, Fowler T, Davies SC. Tackling the threat of antimicrobial resistance: from policy to sustainable action. Philos Trans R Soc Lond B Biol Sci. 2015;370(1670):20140082. https://doi.org/10.1098/rstb.2014.0082.
Founou LL, Founou RC, Essack SY. Antibiotic Resistance in the Food Chain: A Developing Country-Perspective. Front Microbiol. 2016; 7:1881. https://doi.org/10.3389/fmicb.2016.01881.
Founou RC, Blocker AJ, Noubom M, et al. The COVID-19 pandemic: a threat to antimicrobial resistance containment. Future Sci OA. 2021; 7(8):FSO736. https://doi.org/10.2144/fsoa-2021-0012.
Rossolini GM, Arena F, Pecile P, Pollini S. Update on the antibiotic resistance crisis. Curr Opin Pharmacol. 2014; 18:56-60. https://doi.org/10.1016/j.coph.2014.09.006.
Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P T. 2015; 40(4):277-83.
Vidovic N, Vidovic S. Antimicrobial Resistance and Food Animals: Influence of Livestock Environment on the Emergence and Dissemination of Antimicrobial Resistance. Antibiotics (Basel). 2020; 9(2):52. https://doi.org/10.3390/antibiotics9020052.
Beović B, Doušak M, Ferreira-Coimbra J, Nadrah K, Rubulotta F, Belliato M, Berger-Estilita J, Ayoade F, Rello J, Erdem H. Antibiotic use in patients with COVID-19: a 'snapshot' Infectious Diseases International Research Initiative (ID-IRI) survey. J Antimicrob Chemother. 2020; 75(11):3386-3390. https://doi.org/10.1093/jac/dkaa326.
Rezasoltani S, Yadegar A, Hatami B, Asadzadeh Aghdaei H, Zali MR. Antimicrobial Resistance as a Hidden Menace Lurking Behind the COVID-19 Outbreak: The Global Impacts of Too Much Hygiene on AMR. Front Microbiol. 2020; 11:590683. https://doi.org/10.3389/fmicb.2020.590683.
Singh S, Rehman S, Fatima Z, Hameed S. Protein kinases as potential anticandidal drug targets. Front Biosci (Landmark Ed). 2020; 25:1412-1432. https://doi.org/10.2741/4862.
EU. Antimicrobial resistance. European Commission; 2017 http://ec.europa.eu/ dgs/health food-safety/amr/index en.htm.
Mossialos E, Morel C, Edwards S, Berenson J, Gemmill-Toyama M, Brogan D. Policies and incentives for promoting innovation in antibiotic research. Copenhagen: World Health Organization; 2010.
David KB, Adebisi YA. Proposed model for hospital and community pharmacy services during COVID-19 pandemic in Nigeria. Int J Pharm Pract. 2020; 28(5):544-545. https://doi.org/10.1111/ijpp.12652.
Lucero-Prisno D, Adebisi Y, Lin X. Current efforts and challenges facing responses to 2019-nCoV in Africa. Glob Health Res Policy. 2020; 5(1). https://doi.org/10.1186/s41256-020-00148-1.
lein EY, Monteforte B, Gupta A, Jiang W, May L, Hsieh YH, Dugas A. The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis. Influenza Other Respir Viruses. 2016; 10(5):394-403. https://doi.org/10.1111/irv.12398.
Holubar M. Antimicrobial resistance: a global public health emergency further exacerbated by international travel. J Travel Med. 2020 Feb 3; 27(1):taz095. https://doi.org/10.1093/jtm/taz095.
Rasheed F, Saeed M, Alikhan NF, Baker D, Khurshid M, Ainsworth EV, Turner AK, Imran AA, Rasool MH, Saqalein M, Nisar MA, Fayyaz Ur Rehman M, Wain J, Yasir M, Langridge GC, Ikram A. Emergence of Resistance to Fluoroquinolones and Third-Generation Cephalosporins in Salmonella Typhi in Lahore, Pakistan. Microorganisms. 2020; 8(9):1336. https://doi.org/10.3390/microorganisms8091336.
Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, Soucy JR, Daneman N. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020; 26(12):1622-1629. https://doi.org/10.1016/j.cmi.2020.07.016.
Michael CA, Dominey-Howes D, Labbate M. The antimicrobial resistance crisis: causes, consequences, and management. Front Public Health. 2014; 2:145. https://doi.org/10.3389/fpubh.2014.00145.
Nothias LF, Knight R, Dorrestein PC. Antibiotic discovery is a walk in the park. Proc Natl Acad Sci U S A. 2016; 113(51):14477-14479. https://doi.org/10.1073/pnas.1618221114.
Nelson N, Joshi M, Kirika R. Antimicrobial resistance: the need for action in the East, Central and Southern Africa Region, submitted to the US agency for international development by the strengthening pharmaceutical systems (SPS) program. Arlington, VA: Management Sciences for Health; 2009.
Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev. 2010; 74(3):417-433. https://doi.org/10.1128/MMBR.00016-10.
Knight GM, Glover RE, McQuaid CF, Olaru ID, Gallandat K, Leclerc QJ, Fuller NM, Willcocks SJ, Hasan R, van Kleef E, Chandler CI. Antimicrobial resistance and COVID-19: Intersections and implications. Elife. 2021; 10:e64139. https://doi.org/10.7554/eLife.64139.
Benmerzouga I, Al-Zammay SA, Al-Shammari MM, Alsaif SA, Alhaidan TM, Aljofan M. Practices of patients consuming antibiotics and knowledge about antibiotic resistance in Hail region - Saudi Arabia. Future Sci OA. 2019; 5(10):FSO420. https://doi.org/10.2144/fsoa-2019-0054.
Ganguly NK, Arora NK, Chandy SJ, Fairoze MN, Gill JP, Gupta U, Hossain S, Joglekar S, Joshi PC, Kakkar M, Kotwani A, Rattan A, Sudarshan H, Thomas K, Wattal C, Easton A, Laxminarayan R; Global Antibiotic Resistance Partnership (GARP) - India Working Group. Rationalizing antibiotic use to limit antibiotic resistance in India. Indian J Med Res. 2011; 134(3):281-94.
Nayyar GML, Attaran A, Clark JP, et al. Responding to the pandemic of falsified medicines. Am J Trop Med Hyg. 2015; 92(6 Suppl):113-118. https://doi.org/10.4269/ajtmh.14-0393.
Gill K. A primary evaluation of service delivery under the National Rural Health Mission (NRHM): findings from a study in Andhra Pradesh, Uttar Pradesh, Bihar and Rajasthan. Planning Commission of India, Government of India; 2009
WBG. Drug-resistant infections. A threat to our economic future. World Bank Group; 2016.
Boolchandani M, D'Souza AW, Dantas G. Sequencing-based methods and resources to study antimicrobial resistance. Nat Rev Genet. 2019; 20(6):356-370. https://doi.org/10.1038/s41576-019-0108-4.
Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, Li SB, Wang HY, Zhang S, Gao HN, Sheng JF, Cai HL, Qiu YQ, Li LJ. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020; 368:m606. https://doi.org/10.1136/bmj.m606.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020; 395(10223):497-506. https://doi.org/10.1016/S0140-6736(20)30183-5.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395(10223):507-513. https://doi.org/10.1016/S0140-6736(20)30211-7.
Ruiz J. Enhanced antibiotic resistance as a collateral COVID-19 pandemic effect?. J Hosp Infect. 2021; 107:114-115. https://doi.org/10.1016/j.jhin.2020.11.010.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28; 395(10229):1054-1062. https://doi.org/10.1016/S0140-6736(20)30566-3.
Rawson TM, Moore LSP, Castro-Sanchez E, Charani E, Davies F, Satta G, Ellington MJ, Holmes AH. COVID-19 and the potential long-term impact on antimicrobial resistance. J Antimicrob Chemother. 2020; 75(7):1681-1684. https://doi.org/10.1093/jac/dkaa194.
Huttner BD, Catho G, Pano-Pardo JR, Pulcini C, Schouten J. COVID-19: don't neglect antimicrobial stewardship principles!. Clin Microbiol Infect. 2020 Jul; 26(7):808-810. https://doi.org/10.1016/j.cmi.2020.04.024.
Huang Q, Deng X, Li Y, Sun X, Chen Q, Xie M, Liu S, Qu H, Liu S, Wang L, He G, Gong Z. Clinical characteristics and drug therapies in patients with the common-type coronavirus disease 2019 in Hunan, China. Int J Clin Pharm. 2020 Jun; 42(3):837-845. https://doi.org/10.1007/s11096-020-01031-2.
Zavala-Flores E, Salcedo-Matienzo J. Medicación prehospitalaria en pacientes hospitalizados por COVID-19 en un hospital público de Lima-Perú. Acta Med Peru. 2020; 37. https://doi.org/org/10.35663/amp.2020.373.1277.
Firth A, Prathapan P. Azithromycin: The First Broad-spectrum Therapeutic. Eur J Med Chem. 2020; 207:112739. https://doi.org/10.1016/j.ejmech.2020.112739.
Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Tissot Dupont H, Honoré S, Colson P, Chabrière E, La Scola B, Rolain JM, Brouqui P, Raoult D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020; 56(1):105949. https://doi.org/10.1016/j.ijantimicag.2020.
Clancy CJ, Schwartz IS, Kula B, Nguyen MH. Bacterial Superinfections Among Persons With Coronavirus Disease 2019: A Comprehensive Review of Data From Postmortem Studies. Open Forum Infect Dis. 2021; 8(3):ofab065. https://doi.org/10.1093/ofid/ofab065.
He Y, Li W, Wang Z, Chen H, Tian L, Liu D. Nosocomial infection among patients with COVID-19: A retrospective data analysis of 918 cases from a single center in Wuhan, China. Infect Control Hosp Epidemiol. 2020; 41(8):982-983. https://doi.org/10.1017/ice.2020.126.
Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, Satta G, Cooke G, Holmes A. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. Clin Infect Dis. 2020; 71(9):2459-2468. https://doi.org/10.1093/cid/ciaa530.
Manohar P, Loh B, Athira S, et al. Secondary Bacterial Infections During Pulmonary Viral Disease: Phage Therapeutics as Alternatives to Antibiotics?. Front Microbiol. 2020; 11:1434. https://doi.org/10.3389/fmicb.2020.01434.
Wang L, He W, Yu X, Hu D, Bao M, Liu H, Zhou J, Jiang H. Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. J Infect. 2020 Jun; 80(6):639-645. https://doi.org/10.1016/j.jinf.2020.03.019.
Kim D, Quinn J, Pinsky B, Shah NH, Brown I. Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens. JAMA. 2020 May 26; 323(20):2085-2086. https://doi.org/10.1001/jama.2020.6266.
Mack I, Sharland M, Berkley JA, Klein N, Malhotra-Kumar S, Bielicki J. Antimicrobial Resistance Following Azithromycin Mass Drug Administration: Potential Surveillance Strategies to Assess Public Health Impact. Clin Infect Dis. 2020; 70(7):1501-1508. https://doi.org/10.1093/cid/ciz893.
Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology. 2015; 23(5):231-69. https://doi.org/10.1007/s10787-015-0239-y.
Arastehfar A, Carvalho A, Nguyen MH, et al. COVID-19-Associated Candidiasis (CAC): An Underestimated Complication in the Absence of Immunological Predispositions?. J Fungi (Basel). 2020; 6(4):211. https://doi.org/10.3390/jof6040211.
Chowdhary A, Sharma A. The lurking scourge of multidrug resistant Candida auris in times of COVID-19 pandemic. J Glob Antimicrob Resist. 2020; 22:175-176. https://doi.org/10.1016/j.jgar.2020.06.003.
Porretta AD, Baggiani A, Arzilli G, et al. Increased Risk of Acquisition of New Delhi Metallo-Beta-Lactamase-Producing Carbapenem-Resistant Enterobacterales (NDM-CRE) among a Cohort of COVID-19 Patients in a Teaching Hospital in Tuscany, Italy. Pathogens. 2020; 9(8):635. https://doi.org/10.3390/pathogens9080635.
Cantón R, Gijón D, Ruiz-Garbajosa P. Antimicrobial resistance in ICUs: an update in the light of the COVID-19 pandemic. Curr Opin Crit Care. 2020; 26(5):433-441. https://doi.org/10.1097/MCC.0000000000000755.
Gomez-Simmonds A, Annavajhala MK, McConville TH, Dietz DE, Shoucri SM, Laracy JC, Rozenberg FD, Nelson B, Greendyke WG, Furuya EY, Whittier S, Uhlemann AC. Carbapenemase-producing Enterobacterales causing secondary infections during the COVID-19 crisis at a New York City hospital. J Antimicrob Chemother. 2021; 76(2):380-384. https://doi.org/10.1093/jac/dkaa466.
Fattorini L, Creti R, Palma C, Pantosti A. Bacterial coinfections in COVID-19: an underestimated adversary. Annali dell'Istituto superiore di sanita. 2020; 56(3):359-64.
Sermo, Breaking results: Sermo’s COVID-19 real time barometer study WAVE I: March 25–27, (n.d.).
Baron SA, Devaux C, Colson P, Raoult D, Rolain JM. Teicoplanin: an alternative drug for the treatment of COVID-19?. Int J Antimicrob Agents. 2020; 55(4):105944. https://doi.org/10.1016/j.ijantimicag.2020.105944.
Antimicrobial resistance in the age of COVID-19. Nat Microbiol. 2020; 5(6):779. https://doi.org/10.1038/s41564-020-0739-4.
Contou D, Claudinon A, Pajot O, Micaëlo M, Longuet Flandre P, Dubert M, Cally R, Logre E, Fraissé M, Mentec H, Plantefève G. Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU. Ann Intensive Care. 2020; 10(1):119. https://doi.org/10.1186/s13613-020-00736-x.
Cox MJ, Loman N, Bogaert D, O'Grady J. Co-infections: potentially lethal and unexplored in COVID-19. Lancet Microbe. 2020; 1(1):e11. https://doi.org/10.1016/S2666-5247(20)30009-4.
Zafer MM, El-Mahallawy HA, Ashour HM. Severe COVID-19 and Sepsis: Immune Pathogenesis and Laboratory Markers. Microorganisms. 2021 J; 9(1):159. https://doi.org/10.3390/microorganisms9010159.
Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020; 81(2):266-275. https://doi.org/10.1016/j.jinf.2020.05.046.
Clancy CJ, Nguyen MH. Coronavirus Disease 2019, Superinfections, and Antimicrobial Development: What Can We Expect? Clin Infect Dis. 2020; 71(10):2736-2743. https://doi.org/10.1093/cid/ciaa524.
Egyir B, Obeng-Nkrumah N, Kyei GB. COVID-19 pandemic and antimicrobial resistance: Another call to strengthen laboratory diagnostic capacity in Africa. Afr J Lab Med. 2020; 9(1):1302. https://doi.org/10.4102/ajlm.v9i1.1302.
Getahun H, Smith I, Trivedi K, Paulin S, Balkhy HH. Tackling antimicrobial resistance in the COVID-19 pandemic. Bull World Health Organ. 2020; 98(7):442-442A. https://doi.org/10.2471/BLT.20.268573.
Seale AC, Gordon NC, Islam J, Peacock SJ, Scott JAG. AMR Surveillance in low and middle-income settings - A roadmap for participation in the Global Antimicrobial Surveillance System (GLASS). Wellcome Open Res. 2017; 2:92. https://doi.org/10.12688/wellcomeopenres.12527.1.
Bivins A, North D, Ahmad A, Ahmed W, Alm E, Been F et al. Wastewater-Based Epidemiology: Global Collaborative to Maximize Contributions in the Fight Against COVID-19. Environmental Science & Technology. 2020; 54(13):7754-7757. https://doi.org/10.1021/acs.est.0c02388.
Fishman N. Society for Healthcare Epidemiology of America, Infectious Diseases Society ofAmerica, Pediatric Infectious Diseases Society, Policy Statement on Antimicrobial Stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). Infect Control Hosp Epidemiol. 2012; 33:322–7. https://doi.org/10.1086/665010.
Stevens MP, Patel PK, Nori P. Involving antimicrobial stewardship programs in COVID-19 response efforts: All hands on deck. Infect Control Hosp Epidemiol. 2020; 41(6):744-745. https://doi.org/10.1017/ice.2020.69.
Jones KA, Watson M, Jacob JT, Wiley Z. Antimicrobial stewardship interventions to minimize healthcare worker exposure to SARS-CoV-2. Infect Control Hosp Epidemiol. 2021; 42(5):645-646. https://doi.org/10.1017/ice.2020.302.
Velasco-Arnaiz E, López-Ramos MG, Simó-Nebot S, Jordan I, Ríos-Barnés M, Urrea-Ayala M, Monsonís M, Fortuny C, Noguera-Julian A; Kids Corona project. Pediatric antimicrobial stewardship in the COVID-19 outbreak. Infect Control Hosp Epidemiol. 2021; 42(5):642-644. https://doi.org/10.1017/ice.2020.312.
Published
Abstract Display: 679 
PDF Downloads: 667 PDF Downloads: 31 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.